Gland Pharma Limited
Nippon India Mutual Fund decreased its stake in Gland Pharma Limited from 5.04% to 4.93% by selling 170,320 shares. This transaction caused the fund to cross the 5% disclosure threshold.
A vertically integrated injectable-focused pharmaceutical company, Gland Pharma develops, manufactures, and markets complex injectables for global markets across the United States, Europe, Canada, Australia, and India. Established in Hyderabad in 1978, the company operates on a business-to-business model and serves customers in over 60 countries worldwide. Known for its expertise in complex injectable formulations, it maintains a strong presence across the value chain. Gland Pharma is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.